Special Issue

Antibiotic Resistant Pathogens in Hospital

Message from the Guest Editors

The emergence of antimicrobial resistance (AMR) is a major public health problem for contemporary medicine. Antibiotic-resistant pathogens can cause difficult-totreat infections in hospitalized patients and in immunocompromised hosts. The over-prescription of antibiotics has been witnessed, almost on a worldwide scale, during the SARS-CoV2 pandemic, and the increasing rates of antibiotic-resistant pathogens is threatening. This Special Issue addresses any aspect of antibiotic-resistant pathogens in hospitals, including the following areas: Epidemiology; Infection control measures to prevent or contain the expansion of antibiotic-resistant pathogens; Diagnostic tools to guide early and appropriate treatment against antibioticresistant pathogens; Therapeutic strategies to treat infections caused by antibiotic-resistant pathogens; Antimicrobial stewardship studies to combat antibioticresistant pathogens and avoid antimicrobial over-use. Keywords: antimicrobial resistance; healthcareassociated infections; resistance mechanisms; betalactams; colistin; carbapenem; Klebsiella pneumoniae; Pseudomonas aeruginosa; Acinetobacter baumannii; nosocomial pneumonia

Guest Editors

Dr. Garyphallia Poulakou

Dr. Marios Karvouniaris

Prof. Dr. Matteo Bassetti

Deadline for manuscript submissions

closed (31 January 2024)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/126182

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

